Likelihood estimation of drug occupancy for brain PET studies

被引:10
|
作者
Schain, Martin [1 ]
Zanderigo, Francesca [1 ,2 ]
Ogden, R. Todd [1 ,2 ,3 ]
机构
[1] Columbia Univ, Dept Psychiat, New York, NY USA
[2] New York State Psychiat Inst & Hosp, Mol Imaging & Neuropathol Div, New York, NY 10032 USA
[3] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY USA
关键词
POSITRON-EMISSION-TOMOGRAPHY; IN-VIVO; SEROTONIN TRANSPORTER; QUANTIFICATION; BINDING; HUMANS; SYSTEM; NEURORECEPTOR;
D O I
10.1016/j.neuroimage.2018.05.017
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Neuroimaging with PET is unique in its capability to measure in vivo the occupancy of a drug. The occupancy is typically obtained by conducting PET measurements before and after administration of the drug. For radioligands for which no reference region exists, however, the only established procedure to estimate the occupancy from these data is via linear regression analysis, forming the basis for the so-called Lassen plot. There are several reasons why simple linear regression analysis is not ideal for analyzing these data, including regression attenuation and correlated errors. Here, we propose the use of Likelihood Estimation of Occupancy (LEO) in such a situation. Similar to the Lassen plot, LEO uses the total distribution volume estimates at baseline and at block condition as input, but estimates the non-displaceable distribution volume (V-ND) and fractional occupancy (Delta) via direct maximum likelihood estimation (MLE). This study outlines the rationale for using MLE to estimate Delta and V-ND from PET data, and evaluates its performance in relation to the Lassen Plot via two separate simulation experiments. Finally, LEO and Lassen plot are applied to a PET dataset acquired with [C-11]WAY-100635. LEO can exploit the covariance structure of the data to improve the accuracy and precision of the estimates of Delta and V-ND. Theoretically, the covariance matrix can be extracted from a test-retest dataset for the radioligand at hand. Several procedures to estimate the covariance matrix were considered as part of the simulation experiments, and the effect of the test-retest sample size was also assessed. The results are conclusive in that MLE can be used to estimate Delta and V-ND from PET data, avoiding the limitations associated with linear regression. The performance of LEO was, naturally, dependent on the procedure used to estimate the covariance matrix, and the test-retest sample size. Given a test-retest sample size of at least 5, but preferably 10 individuals, LEO provides higher accuracy and precision than Lassen plot in the estimation of Delta and V-ND. We conclude that LEO is valuable in drug occupancy studies.
引用
收藏
页码:255 / 265
页数:11
相关论文
共 50 条
  • [31] Human Brain Imaging of α7 nAChR with [18F]ASEM: a New PET Radiotracer for Neuropsychiatry and Determination of Drug Occupancy
    Wong, Dean F.
    Kuwabara, Hiroto
    Pomper, Martin
    Holt, Daniel P.
    Brasic, James R.
    George, Noble
    Frolov, Boris
    Willis, William
    Gao, Yongjun
    Valentine, Heather
    Nandi, Ayon
    Gapasin, Lorena
    Dannals, Robert F.
    Horti, Andrew G.
    [J]. MOLECULAR IMAGING AND BIOLOGY, 2014, 16 (05) : 730 - 738
  • [32] Human Brain Imaging of α7 nAChR with [18F]ASEM: a New PET Radiotracer for Neuropsychiatry and Determination of Drug Occupancy
    Dean F. Wong
    Hiroto Kuwabara
    Martin Pomper
    Daniel P. Holt
    James R. Brasic
    Noble George
    Boris Frolov
    William Willis
    Yongjun Gao
    Heather Valentine
    Ayon Nandi
    Lorena Gapasin
    Robert F. Dannals
    Andrew G. Horti
    [J]. Molecular Imaging and Biology, 2014, 16 : 730 - 738
  • [33] PET imaging studies in drug abuse
    Fowler, JS
    Volkow, ND
    [J]. JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1998, 36 (03): : 163 - 174
  • [34] Stratification of PET studies in drug evaluation
    Bauer, A
    Weber, S
    Coenen, HH
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (07) : S92 - S92
  • [35] A weighted method for estimation of receptor occupancy for pharmacodynamic measurements in drug development
    Sternebring, Ola
    Alifrangis, Lene
    Christensen, Toke Folke
    Ji, Hong
    Hegelund, Anne Charlotte
    Hogerkorp, Carl-Magnus
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2016, 90 (02) : 220 - 229
  • [36] ANTIPSYCHOTIC DRUG-THERAPY IN SCHIZOPHRENICS - STUDIES OF RECEPTOR OCCUPANCY
    HIRSCHOWITZ, J
    VALLABHAJOSULA, S
    INTRATOR, J
    HITZEMANN, R
    DACOSTA, M
    MACHAC, J
    [J]. BIOLOGICAL PSYCHIATRY, 1994, 35 (09) : 691 - 691
  • [37] Specification and estimation of sources of bias affecting neurological studies in PET/MR with an anatomical brain phantom
    Teuho, J.
    Johansson, J.
    Linden, J.
    Saunavaara, V.
    Tolvanen, T.
    Teras, M.
    [J]. NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT, 2014, 734 : 179 - 184
  • [38] Estimation of the binding potential BPND without a reference region or blood samples for brain PET studies
    Schain, Martin
    Zanderigo, Francesca
    Mann, J. John
    Ogden, R. Todd
    [J]. NEUROIMAGE, 2017, 146 : 121 - 131
  • [39] Motion correction in PET brain studies
    Herzog, H
    Tellman, L
    Fulton, R
    Pietrzyk, U
    [J]. FOURTH INTERNATIONAL WORKSHOP ON MULTIDIMENSIONAL SYSTEMS - NDS 2005, 2005, : 178 - 181
  • [40] PET studies of brain monoamine transporters
    Laakso, A
    Hietala, J
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (16) : 1611 - 1623